<DOC>
	<DOC>NCT01338831</DOC>
	<brief_summary>The purpose of this first multi-dose study in cancer patients is to determine the maximum tolerated dose (MTD) or recommended phase II dose (RP2D), characterize the safety, tolerability and pharmacokinetics profile. Once the MTD has been established and/or a RP2D chosen, the study will enroll patients into the expansion portion of the study.</brief_summary>
	<brief_title>Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>1. Histologically confirmed diagnosis of prostate cancer, breast cancer, or uterine leiomyoma 2. Detectable metastases by bone scan, CTscan, or MRI. 3. Presence of prolactin receptor in primary or metastatic tumor (Dose Escalation only) 4. Suitable venous access for blood sampling 1. Prior treatment with any antiprolactin receptor antibody 2. Major surgery within 28 days before study treatment 3. Patients who have received radiotherapy â‰¤ 2 weeks prior to starting study drug 4. Prior anaphylactic or other severe infusion reaction to antibody formulations Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>prostate cancer,</keyword>
	<keyword>breast cancer,</keyword>
	<keyword>prolactin,</keyword>
	<keyword>prolactin receptor</keyword>
	<keyword>uterine leiomyoma</keyword>
</DOC>